In addition, the TEX signature can characterize the immune environment in LUAD patients and accurately evaluate the prognosis of LUAD patients, providing new ideas for clinical treatment of lung adenocarcinoma. This evidence concerns the gene TEX46 and lung adenocarcinoma.